^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Estrogen receptor agonist

    Related drugs:
    17h
    A Study in Japanese Healthy Men to Test How Well Different Doses of BI 3031185 Are Tolerated and a Study in Japanese Healthy Women to Test Whether BI 3031185 Influences the Amount of a Contraceptive in the Blood (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Boehringer Ingelheim
    New P1 trial
    |
    midazolam hydrochloride
    1d
    CLOMINOA: Interest of Clomiphene Citrate in Patients With Non-obstructive Azoospermia on the Quantity of Sperm Cells (clinicaltrials.gov)
    P3, N=0, Withdrawn, Hospices Civils de Lyon | N=128 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    7d
    The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial (clinicaltrials.gov)
    P3, N=110, Recruiting, Main Line Health | Trial completion date: Aug 2026 --> Dec 2028 | Trial primary completion date: Feb 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Orgovyx (relugolix)
    16d
    Evaluation of a Long Versus Short Clomid Protocol for Controlled Ovarian Stimulation (clinicaltrials.gov)
    P4, N=120, Recruiting, University of Southern California | Trial completion date: Dec 2027 --> Jun 2028 | Trial primary completion date: Mar 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    1m
    SERENE: Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy (clinicaltrials.gov)
    P3, N=1164, Completed, Sumitomo Pharma Switzerland GmbH | Active, not recruiting --> Completed
    Trial completion
    |
    Orgovyx (relugolix)
    1m
    Mechanistic Insights into the Therapeutic Effects of Zishen Yutai Pill on Premature Ovarian Insufficiency via the RIPK1/RIPK3/MLKL Necroptosis Pathway. (PubMed, Comb Chem High Throughput Screen)
    ZYP ameliorates CTX-induced POI by regulating hormones, improving ovarian morphology, and inhibiting the RIPK1/RIPK3/MLKL pathway.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • RIPK1 (Receptor Interacting Serine/Threonine Kinase 1) • RIPK3 (Receptor Interacting Serine/Threonine Kinase 3) • MLKL (Mixed Lineage Kinase Domain Like Pseudokinase)
    |
    cyclophosphamide • estradiol valerate
    2ms
    Impact of Estradiol on Endothelial Function in Peri-Menopausal Women (clinicaltrials.gov)
    P4, N=80, Active, not recruiting, University of Delaware | Trial completion date: Jun 2026 --> Oct 2026 | Trial primary completion date: May 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    2ms
    The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, University Hospital, Geneva | Trial completion date: Dec 2026 --> Mar 2027
    Trial completion date
    2ms
    CoCo3-PCOS: CoCo-PCOS - Comprehensive Health Effects of Combined Contraceptives: a 6-month randomized, controlled, open-label trial of E4+DRSP, EE20g+DRSP, and DRSP-only in women with PCOS (2025-523358-15-00)
    P4, N=156, Not yet recruiting, Pohjois-Pohjanmaan hyvinvointialue, University Of Oulu
    New P4 trial
    2ms
    TeenVIBE: Teen Vulnerability to Irritability: Brain and Estrogen Changes (clinicaltrials.gov)
    P4, N=50, Not yet recruiting, University of North Carolina, Chapel Hill
    New P4 trial
    2ms
    CoCo3 - Comprehensive Health Effects of Combined Contraceptives: a 12-month randomized, controlled, open-label trial comparing E4+DRSP, EE 20?g+DRSP and DRSP-only (2025-523359-71-00)
    P4, N=156, Not yet recruiting, Pohjois-Pohjanmaan hyvinvointialue, University Of Oulu
    New P4 trial
    2ms
    PERT: Intravenous Estrogen in Kidney Transplant Study (clinicaltrials.gov)
    P1/2, N=30, Active, not recruiting, University of Pennsylvania | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date